CD274 and neoplasm: They reported a RR of 25% for the small NET subgroup and, interestingly, a significantly higher RR in patients with TMB‐high or PD‐L1 expression ≥10% compared to those that had TMB‐low tumours (75.0% vs. 16.1%, p = 0.03) or PD‐L1 < 10% (50.0% vs. 10.7%, p = 0.019), while 3 of the 8 (37.5%) responders harboured ARID1A mutations.